The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Pan, Min, Wright, William C., Chapple, Richard H., Zubair, Asif, Sandhu, Manbir, Batchelder, Jake E., Huddle, Brandt C., Low, Jonathan, Blankenship, Kaley B., Wang, Yingzhe, Gordon, Brittney, Archer, Payton, Brady, Samuel W., Natarajan, Sivaraman, Posgai, Matthew J., Schuetz, John, Miller, Darcie, Kalathur, Ravi, Chen, Siquan, Connelly, Jon Patrick, Babu, M. Madan, Dyer, Michael A., Pruett-Miller, Shondra M., Freeman, Burgess B., Chen, Taosheng, Godley, Lucy A., Blanchard, Scott C., Stewart, Elizabeth, Easton, John, Geeleher, Paul
Published in Nature communications (09.11.2021)
Published in Nature communications (09.11.2021)
Get full text
Journal Article
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Pan, Min, Wright, William C, Chapple, Rich, Zubair, Asif, Sandhu, Manbir, Batchelder, Jake, Low, Jonathan, Blankenship, Kaley B, Wang, Yingzhe, Gordon, Brittney, Archer, Payton, Brady, Samuel W, Sivaraman Natarajan, Posgai, Matthew J, Schuetz, John, Miller, Darcie, Kalathur, Ravi, Chen, Siquan, Connelly, Jon Patrick, M Madan Babu, Dyer, Michael A, Pruett-Miller, Shondra M, Freeman, Burgess B, Chen, Taosheng, Godley, Lucy A, Blanchard, Scott, Stewart, Elizabeth, Easton, John, Geeleher, Paul
Published in bioRxiv (25.02.2021)
Published in bioRxiv (25.02.2021)
Get full text
Paper